Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Trial for Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome

Trial Profile

A Trial for Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 07 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cladribine (Primary) ; Cytarabine (Primary) ; Cytarabine/daunorubicin (Primary) ; Decitabine (Primary) ; Fludarabine (Primary) ; Ganetespib (Primary) ; Gemtuzumab ozogamicin (Primary) ; Idarubicin (Primary) ; Quizartinib (Primary) ; Vosaroxin (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AML-18
  • Most Recent Events

    • 02 Oct 2019 Recruitment completion is expected on 28 Feb 2021 according to ISRCTN.
    • 13 Jul 2016 This trial was suspended in Denmark, according to European Clinical Trials Database.
    • 03 Mar 2016 Accrual to date is 17% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top